{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:52:22Z","timestamp":1785541942453,"version":"3.56.0"},"reference-count":24,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T00:00:00Z","timestamp":1552348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5UG1CA189974"],"award-info":[{"award-number":["5UG1CA189974"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","award":["CI-53-10"],"award-info":[{"award-number":["CI-53-10"]}],"id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2019,6,15]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Aromatase inhibitor (AI)\u2010associated musculoskeletal symptoms (AIMSS) negatively impact adherence to and persistence with therapy. In SWOG S1202, patients with AIMSS who were treated with duloxetine, a serotonin norepinephrine reuptake inhibitor, reported improvement in pain by 12\u00a0weeks compared with placebo. Based on the authors\u2019 prior observation that responses to pain interventions differ between obese and nonobese patients, the current study examined whether response to duloxetine therapy differed by obesity status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In SWOG S1202, a total of 299 AI\u2010treated postmenopausal women with stage I to III (AJCC 7th Edition) breast cancer who developed new or worsening average pain were enrolled, randomized to duloxetine or placebo, and treated for 12\u00a0weeks. Patient\u2010reported outcomes were obtained at baseline and through 12\u00a0weeks. Patients were categorized into nonobese (body mass index [BMI] &lt;30\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) or obese (BMI \u226530\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ). The authors tested the interaction between intervention and obesity with respect to average pain at 12\u00a0weeks in the 289 eligible patients, using a\n                      <jats:italic>P<\/jats:italic>\n                      value of .05 to indicate statistical significance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In approximately 54% of evaluable patients with a BMI \u226530\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , the reduction in the mean average pain score between baseline and 12\u00a0weeks was statistically significantly greater for patients treated with duloxetine compared with those receiving placebo (\u20102.73 vs \u20101.64 points;\n                      <jats:italic>P\u00a0<\/jats:italic>\n                      =\u00a0.003). Conversely, in the nonobese patients, the reduction in the mean average pain score was similar in the 2 cohorts (\u20102.46 vs \u20102.34 points;\n                      <jats:italic>P\u00a0<\/jats:italic>\n                      =\u00a0.75). The\n                      <jats:italic>P<\/jats:italic>\n                      value for interaction was .02, thereby meeting the threshold criteria of the current study. Similar findings were evident for other pain\u2010related patient\u2010reported outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this trial, obese patients with AIMSS obtained more analgesic benefit from duloxetine compared with nonobese patients. Additional studies are warranted to determine the biologic basis for these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.32024","type":"journal-article","created":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T15:04:05Z","timestamp":1552403045000},"page":"2123-2129","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Association between body mass index and response to duloxetine for aromatase inhibitor\u2010associated musculoskeletal symptoms in SWOG S1202"],"prefix":"10.1002","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4771-5930","authenticated-orcid":false,"given":"N. Lynn","family":"Henry","sequence":"first","affiliation":[{"name":"Department of Internal Medicine University of Utah Huntsman Cancer Institute  Salt Lake City Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Unger","sequence":"additional","affiliation":[{"name":"SWOG Statistics and Data Management Center  Seattle Washington"},{"name":"Cancer Prevention Program, Fred Hutchinson Cancer Research Center  Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathee","family":"Till","sequence":"additional","affiliation":[{"name":"SWOG Statistics and Data Management Center  Seattle Washington"},{"name":"Cancer Prevention Program, Fred Hutchinson Cancer Research Center  Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne F.","family":"Schott","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine University of Michigan  Ann Arbor Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine D.","family":"Crew","sequence":"additional","affiliation":[{"name":"Department of Medicine Columbia University  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danika L.","family":"Lew","sequence":"additional","affiliation":[{"name":"SWOG Statistics and Data Management Center  Seattle Washington"},{"name":"Cancer Prevention Program, Fred Hutchinson Cancer Research Center  Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Fisch","sequence":"additional","affiliation":[{"name":"AIM Specialty Health  Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol M.","family":"Moinpour","sequence":"additional","affiliation":[{"name":"Cancer Prevention Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center  Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"James L.","family":"Wade","sequence":"additional","affiliation":[{"name":"Heartland National Cancer Institute Community Oncology Research Program  Decatur Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn L.","family":"Hershman","sequence":"additional","affiliation":[{"name":"Department of Medicine Columbia University  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3756"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.8619"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0261"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70182-7"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70328-X"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.1547"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.6651"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.8907"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5595"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/83.6.1505S"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.90"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05485"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4946-0"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(83)90143-4"},{"key":"e_1_2_8_16_1","first-page":"1833","article-title":"Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee","volume":"15","author":"Bellamy N","year":"1988","journal-title":"J Rheumatol"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh360"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006263818115"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1179\/jmt.2009.17.3.163"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/039463201002300204"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-4887.2010.00287.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2014.08.010"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200948030-00005"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2014.01079"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02845.x"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.32024","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.32024","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.32024","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.32024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:57:03Z","timestamp":1761893823000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.32024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,6,15]]}},"alternative-id":["10.1002\/cncr.32024"],"URL":"https:\/\/doi.org\/10.1002\/cncr.32024","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,12]]},"assertion":[{"value":"2018-11-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}